ABOS - CIK 0001576885
The table below shows Acumen Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $51.80M | $46.83M | $36.81M | $30.16M | $33.18M | $67.95M |
| Short-term investments | $76.60M | $79.78M | $106.56M | $118.99M | $167.16M | $192.52M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $133.09M |
| $132.15M |
| $148.40M |
| $154.95M |
| $207.63M |
| $266.92M |
| Property, plant & equipment | $91.00K | $115.00K | $130.00K | $137.00K | $89.00K | $105.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $133.63M | $142.22M | $171.90M | $204.48M | $266.98M | $288.91M |
| Accounts payable | $1.66M | $682.00K | $2.10M | $1.06M | $2.34M | $4.21M |
| Total current liabilities | $29.23M | $21.96M | $24.86M | $19.32M | $19.91M | $15.37M |
| Long-term debt | $16.92M | $27.05M | $29.88M | $29.53M | $29.67M | $29.38M |
| Total liabilities | $46.15M | $49.05M | $54.82M | $48.96M | $49.77M | $44.97M |
| Retained earnings | -$467.20M | -$421.32M | -$394.87M | -$353.92M | -$287.97M | -$258.21M |
| Total equity | $87.48M | $93.17M | $117.08M | $155.52M | $217.20M | $243.95M |